# The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 49


For regulation 66 (amendment of regulation 60 (conditions of UK marketing authorisation: exceptional circumstances)) substitute—
“66. In regulation 60—
(a) after “UK marketing authorisation” in each place it occurs (including the heading to the regulation) insert “or parallel import licence”;
(b) after “the authorisation” in each place it occurs insert “or licence”;
(c) in paragraph (3), after “an authorisation” insert “or licence”;
(d) for paragraph (9) substitute—
“(9) The licensing authority must notify the EMA of any UKMA(NI) or UKMA(UK) that it has granted subject to a condition included in accordance with this regulation.”;
(e) in paragraph (10), after “a marketing authorisation” insert “or licence”.”.

---
Source: https://www.legislation.gov.uk/ukdsi/2020/9780348213980/schedule/2/paragraph/49 (the official version)
Page: https://openlegislation.uk/draft-human-medicines-amendment-etc-eu-exit-regulations-2020/schedule-2/paragraph-49
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.